BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Thermo Fisher’s PPD™ Clinical Research Joins AstraZeneca BioVentureHub for R&D Partnership in Sweden

The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, announced a new research and development ...

October 01, 2025 | News

Japan Grants Orphan Drug Designation to JR-446 for Sanfilippo Syndrome Type B

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japa...

October 01, 2025 | News

AbbVie Submits FDA Application for Tavapadon After Positive Phase 3 TEMPO Results in Parkinson’s Disease

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive r...

September 29, 2025 | News

Merck and Siemens Forge Digital Alliance to Transform Drug Discovery and Manufacturing

Memorandum of Understanding signed to deliver end-to-end digital workflows from drug discovery to manufacturing Combines technology from the Siemens...

September 24, 2025 | News

Akeso Doses First Patient in Phase II Study of Novel TIGIT/TGF-β Bifunctional Antibody for Pancreatic Cancer

Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independent...

September 23, 2025 | News

Galux Validates AI-Driven Platform with Atomic-Level Precision in De Novo Antibody Design

Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...

September 23, 2025 | News

Lunit and Agilent Forge Collaboration to Develop AI-Powered Companion Diagnostics

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...

September 23, 2025 | News

Sanofi and Regeneron Receive CHMP Recommendation for Dupixent in Chronic Spontaneous Urticaria in EU

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo ...

September 23, 2025 | News

Lenovo Launches GOAST v4.0 Slashing Genome Analysis to 24 Minutes with 3x Higher Throughput

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries Lenovo shared updates ...

September 22, 2025 | News

Alnylam Joins Illumina and NashBio’s Alliance for Genomic Discovery

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members levera...

September 19, 2025 | News

Kexing Biopharm Completes FDA Type II DMF Registration for Stem Cell-Derived Exosomes

Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Ma...

September 18, 2025 | News

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

September 16, 2025 | News

Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...

September 16, 2025 | News

Stay Connected